Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

BioNTech & Cardiol Therapeutics – on the verge of a breakout

Compared with the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition t...

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...

Stars align for a silver bull market? Primary silver miners may be poised to shine

By Faith Ashmore 2023 marked another year of a pronounced supply-demand deficit in silver, driven by record industrial demand from robust global investments in the green economy. The most significant increase came from photovoltaics. In a recent revision for 2023,...

2023, the dawn of the silver boom

By Chen Lin, chenpicks.com This year saw another year of the huge supply-demand deficit in silver, despite heavy investment selling. The most significant demand increase came from solar panels. In 2021, the Silver Institute and Metal Focus group were looking at PV (...

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...

It’s Time to Start Talking about the Elephant in the Room

By Jonathan Goodman We at Dundee Goodman Merchant Partners have spent most of our working lives in the resource industry. Collectively we are money managers, geologists, engineers, mining operators, and natural resource/mining bankers. Moreover, all of us are person...

Buzz on the Bullboards: Energy Remains in Focus During Ukraine Crisis

(File image.) The cost of living just keeps getting more expensive. This week saw headlines in the news around the rise in US inflation, up 8.5% over the year to the end of March, to hit its highest rate since 1981. The war in Ukraine drove up energy costs f...

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...
1 2 3 4 5 6 7 8 9 10 ...